PRIMARY MYELOFIBROSIS

This study is testing whether a drug called tasquinimod can help control myelofibrosis, a serious bone marrow cancer. It will be given either by itself or alongside an existing drug (ruxolitinib) to 33 adults whose current treatments aren't working well enough. The main goals are…

This study is testing whether canakinumab, an anti-inflammatory injection given every 3 weeks, can help control myelofibrosis. Researchers want to see if it reduces symptoms like fatigue and enlarged spleen, improves anemia, and is safe for patients. The trial is for adults with …

This study is for people with myelofibrosis, a serious bone marrow cancer, who are not getting the best results from their current standard medication (ruxolitinib). It will test if adding a new drug called navtemadlin to the standard treatment works better and is safe. About 600…

This early-stage trial is testing a new oral medication called AJ1-11095 for adults with myelofibrosis, a serious bone marrow cancer. The study is for patients whose disease didn't respond well to or came back after standard JAK2 inhibitor treatment. Researchers will determine th…

This study is testing whether adding a new drug called iadademstat to an existing treatment (ASTX727) works better for controlling advanced blood cancers. It will involve about 62 adults with specific aggressive forms of myeloproliferative neoplasms (MPNs) that have progressed. T…

This study is testing a two-part treatment for myelofibrosis, a serious bone marrow disease. First, patients take a JAK inhibitor drug. Then, they receive a stem cell transplant from a partially matched donor. The main goal is to see if using the drug for a longer time—before, du…

This study is testing if adding a drug called ruxolitinib to standard treatment can make stem cell transplants safer and more effective for older adults with myelofibrosis or related blood cancers. The main goal is to prevent a dangerous complication where the donor cells attack …

This study continues treatment for 400 people with rare blood cancers who are already benefiting from the drug bomedemstat in earlier trials. Its main goal is to collect long-term safety information and see how well the drug continues to control the disease over time. The study i…

This study is testing an experimental drug called DISC-0974 in people with myelofibrosis or myelodysplastic syndrome who have anemia. The main goals are to see if the drug is safe and if it can help improve red blood cell counts, potentially reducing or eliminating the need for b…

This study is testing an investigational drug called pacritinib against standard care treatments for adults with myelofibrosis, a serious bone marrow cancer, who also have dangerously low platelet counts. The main goals are to see if pacritinib can reduce spleen size and ease dis…

This study is testing whether combining two drugs, momelotinib and luspatercept, can help people with a rare bone marrow cancer called myelofibrosis who need frequent blood transfusions. The main goal is to see if the treatment can reduce or eliminate the need for transfusions ov…

This trial is testing whether a combination of chemotherapy and targeted drugs can better prepare patients with advanced blood cancers for a stem cell transplant. The goal is to control the aggressive cancer enough so patients can safely receive donor stem cells, which may offer …

This study aims to learn how a specific type of immune cell, called a monocyte, behaves in people with certain blood cancers. Researchers will collect blood samples from 70 participants who have not yet started treatment for their condition. By analyzing these cells, they hope to…